Faron Financial Statements From 2010 to 2024

Stocks . UK . 
Stock . Faron Pharmaceuticals Oy
FARN Stock   170.00  2.50  1.49%   
Faron Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Faron Pharmaceuticals Oy investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Faron Pharmaceuticals financial statements helps investors assess Faron Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Faron Pharmaceuticals' valuation are summarized below:
Gross Profit
803 K
Exchange Market
LSE - AIM
Market Capitalization
177.9 M
Revenue
803 K
Earnings Share
(0.31)
There are over eighty-two available fundamental signals for Faron Pharmaceuticals Oy, which can be analyzed over time and compared to other ratios. All traders should verify Faron Pharmaceuticals' prevailing fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction.

Faron Pharmaceuticals Total Revenue

0.0

Check Faron Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Faron Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 185.2 K, Interest Expense of 2.3 M or Selling General Administrative of 9.1 M, as well as many indicators such as . Faron financial statements analysis is a perfect complement when working with Faron Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement various Faron Pharmaceuticals Technical models . Check out the analysis of Faron Pharmaceuticals Correlation against competitors.

Faron Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets10.5 M10.2 M8.6 M
Slightly volatile
Short and Long Term Debt Total13.8 M13.1 M4.7 M
Slightly volatile
Other Current Liabilities2.7 M2.4 M2.2 M
Slightly volatile
Total Current Liabilities15.8 M15 M5.8 M
Slightly volatile
Accounts Payable9.4 M9 M2.7 M
Slightly volatile
Non Current Assets Total1.3 M1.4 M1.2 M
Slightly volatile
Long Term Debt9.9 M9.4 M3.6 M
Slightly volatile
Net Receivables981.9 K1 M831.3 K
Slightly volatile
Common Stock Total Equity2.9 M3.1 M2.5 M
Slightly volatile
Common Stock Shares Outstanding40.5 K68.8 K35.2 K
Slightly volatile
Liabilities And Stockholders Equity10.5 M10.2 M8.6 M
Slightly volatile
Non Current Liabilities Total10.9 M10.4 M3.9 M
Slightly volatile
Other Current Assets2.5 M2 M2 M
Slightly volatile
Total Liabilities26.7 M25.4 M9.8 M
Slightly volatile
Total Current Assets9.2 M8.9 M7.4 M
Slightly volatile
Short Term Debt3.8 M3.6 M1.1 M
Slightly volatile
Intangible Assets691.5 K1.1 M881 K
Slightly volatile
Common Stock2.7 M3.1 M2.4 M
Slightly volatile
Short and Long Term Debt3.6 M3.5 M1.4 M
Very volatile
Cash5.4 M6.9 M5 M
Slightly volatile
Cash And Short Term Investments5.4 M6.9 M5 M
Slightly volatile
Property Plant And Equipment Net195.6 K204 K129 K
Slightly volatile
Property Plant And Equipment Gross198.1 K225 K130.6 K
Slightly volatile
Property Plant Equipment191.9 K376.1 K140.3 K
Slightly volatile
Other Liabilities1.2 M1.2 M627.8 K
Slightly volatile
Capital Stock2.2 M2.4 M2.6 M
Slightly volatile
Capital Lease Obligations240 K213 K353.6 K
Slightly volatile

Faron Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization185.2 K197 K153.9 K
Slightly volatile
Interest Expense2.3 M2.2 M479.2 K
Slightly volatile
Selling General Administrative9.1 M8.7 M3.8 M
Slightly volatile
Other Operating Expenses15.5 M28.6 M12.6 M
Slightly volatile
Research Development12.5 M19.5 M10.3 M
Slightly volatile
Total Operating Expenses15.5 M28.6 M12.6 M
Slightly volatile
Income Tax Expense1.6 M1.5 M341.8 K
Slightly volatile
Gross Profit16.2 K17.1 K178.9 K
Pretty Stable
Interest Income125 K230 K234.5 K
Slightly volatile
Reconciled Depreciation259.3 K346 K162.8 K
Slightly volatile
Selling And Marketing Expenses276.8 K311.4 K339.1 K
Slightly volatile

Faron Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow6.8 M7 M4.7 M
Slightly volatile
Depreciation198.9 K346 K164.9 K
Slightly volatile
Capital Expenditures243.7 K123 K275.8 K
Slightly volatile
Total Cash From Financing Activities15.2 M24 M12.3 M
Slightly volatile
Sale Purchase Of Stock13.1 M16.2 M10.4 M
Slightly volatile
End Period Cash Flow5.4 M6.9 M5 M
Slightly volatile
Issuance Of Capital Stock20.5 M26 M17.9 M
Slightly volatile

Faron Fundamental Market Drivers

Cash And Short Term Investments6.9 M

About Faron Pharmaceuticals Financial Statements

Faron Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Faron Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Faron Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Faron Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue3.3 M3.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
CCitigroup
GMGeneral Motors
FFord Motor

Additional Tools for Faron Stock Analysis

When running Faron Pharmaceuticals' price analysis, check to measure Faron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Faron Pharmaceuticals is operating at the current time. Most of Faron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Faron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Faron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Faron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY